ASTH Quote, Financials, Valuation and Earnings

Biote has a net margin of 3.36% compared to Astrana Health's net margin of 20.83%. Astrana Health's return on equity of 12.67% beat Biote's return on equity of --.

Astrana Health has a consensus price target of $64.5000, signalling upside risk potential of 91.4%. On the other hand Biote has an analysts' consensus of -- which suggests that it could grow by 62.79%. Given that Astrana Health has higher upside potential than Biote, analysts believe Astrana Health is more attractive than Biote.

Astrana Health has a beta of 1.134, which suggesting that the stock is 13.363% more volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health pays 102.24% of its earnings as a dividend. Biote pays out 262.18% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Astrana Health quarterly revenues are $478.7M, which are larger than Biote quarterly revenues of $51.4M. Astrana Health's net income of $16.1M is higher than Biote's net income of $10.7M. Notably, Astrana Health's price-to-earnings ratio is 25.92x while Biote's PE ratio is 23.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.93x versus 1.06x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of 3.36% compared to Astrana Health's net margin of 8.15%. Astrana Health's return on equity of 12.67% beat Cryo-Cell International's return on equity of --.

Astrana Health has a consensus price target of $64.5000, signalling upside risk potential of 91.4%. On the other hand Cryo-Cell International has an analysts' consensus of $9.00 which suggests that it could grow by 14.94%. Given that Astrana Health has higher upside potential than Cryo-Cell International, analysts believe Astrana Health is more attractive than Cryo-Cell International.

Astrana Health has a beta of 1.134, which suggesting that the stock is 13.363% more volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.501, suggesting its less volatile than the S&P 500 by 49.887%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 3.19% to investors and pays a quarterly dividend of $0.25 per share. Astrana Health pays 102.24% of its earnings as a dividend. Cryo-Cell International pays out -- of its earnings as a dividend.

Astrana Health quarterly revenues are $478.7M, which are larger than Cryo-Cell International quarterly revenues of $8M. Astrana Health's net income of $16.1M is higher than Cryo-Cell International's net income of $655.8K. Notably, Astrana Health's price-to-earnings ratio is 25.92x while Cryo-Cell International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.93x versus 2.03x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Evolent Health has a net margin of 3.36% compared to Astrana Health's net margin of -3.72%. Astrana Health's return on equity of 12.67% beat Evolent Health's return on equity of -6.81%.

Astrana Health has a consensus price target of $64.5000, signalling upside risk potential of 91.4%. On the other hand Evolent Health has an analysts' consensus of -- which suggests that it could grow by 123.62%. Given that Evolent Health has higher upside potential than Astrana Health, analysts believe Evolent Health is more attractive than Astrana Health.

Astrana Health has a beta of 1.134, which suggesting that the stock is 13.363% more volatile than S&P 500. In comparison Evolent Health has a beta of 1.448, suggesting its more volatile than the S&P 500 by 44.822%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolent Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health pays 102.24% of its earnings as a dividend. Evolent Health pays out -16.63% of its earnings as a dividend.

Astrana Health quarterly revenues are $478.7M, which are smaller than Evolent Health quarterly revenues of $621.4M. Astrana Health's net income of $16.1M is higher than Evolent Health's net income of -$23.1M. Notably, Astrana Health's price-to-earnings ratio is 25.92x while Evolent Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.93x versus 0.53x for Evolent Health. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 3.36% compared to Astrana Health's net margin of -12.84%. Astrana Health's return on equity of 12.67% beat P3 Health Partners's return on equity of -26.35%.

Astrana Health has a consensus price target of $64.5000, signalling upside risk potential of 91.4%. On the other hand P3 Health Partners has an analysts' consensus of -- which suggests that it could grow by 228.95%. Given that P3 Health Partners has higher upside potential than Astrana Health, analysts believe P3 Health Partners is more attractive than Astrana Health.

Astrana Health has a beta of 1.134, which suggesting that the stock is 13.363% more volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health pays 102.24% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Astrana Health quarterly revenues are $478.7M, which are larger than P3 Health Partners quarterly revenues of $362.1M. Astrana Health's net income of $16.1M is higher than P3 Health Partners's net income of -$46.5M. Notably, Astrana Health's price-to-earnings ratio is 25.92x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.93x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.